Viking Therapeutics
CompanyUnited StatesFounded 2012
Viking Therapeutics develops one asset, in phase 3 (VK2735 in obesity). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in the United States, founded in 2012.
- 1
- Asset
- Furthest stage
- Phase 3
- Raised
- US$1.1bn
- 2
- Trials
- 3
- Signals
Pipeline
1Activates GLP-1 and GIP receptors to regulate appetite and glucose metabolism.
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials2
- Funding rounds and grants2
- Signals6
- Similar companies6
Papers
ADA Scientific Sessions 2026 abstract, 5 Jun 2026